source
- Bristol Myers pushes Cobenfy Alzheimer’s psychosis readout to early 2027 after enrollment delaysBristol Myers Squibb said the Phase 3 readout for its Cobenfy Alzheimer’s psychosis program will be postponed to early 2027. The company had previously expected data from the three Adept trials to…
- Replimune's melanoma virus therapy wins FDA advisory committee vote after two rejectionsReplimune's oncolytic virus RP1, also called vusolimogene oderparepvec and Tudriqev, has been rejected twice by the FDA. Today an advisory committee voted 10 to 3 that the candidate shows enough ef…Fierce Biotech · 1d agoRegulatoryPositive